European Bioanalysis Forum


PDF renditions of the PowerPoint presentations can be viewed and downloaded from this page by clicking the specific point on the program. The program itself can be viewed and downloaded by clicking here.

Program details of the ICH M10 Workshop

08:30 09:00 Welcome – The route to ICH M10 (plenary session)
09:00 10:15 Chapters 1 & 2 (plenary session)
Session moderator: Matthew Barfield, on behalf of the EBF
Session includes a presentation from the JBF (Takashi Miyayama, Chugai Pharmaceutical Co)
10:15 11:00 Coffee break
11:00 13:00 Chapter 3 – Chromatography (breakout session)
Session moderator: Stuart Mc Dougall and Iain Love, on behalf of the EBF
Session includes a presentation from the AAPS (Eric Woolf, MSD)
11:00 13:00 Chapter 4 – LBA (breakout session)
Session moderator: Michaela Golob, Anna Laurén and Robert Nelson, on behalf of the EBF
13:00 14:00 Lunch break
14:00 14:30 Chapter 5 – ISR (plenary session)
Session moderator: Morten Kall, on behalf of the EBF
14:30 14:40 Short logistic break
14:40 16:00 Chapter 6 – Partial and Cross Validation (plenary session)
Session moderators: Tom Verhaeghe and Gwenda Pynaert, on behalf of the EBF
16:00 16:30 Coffee break
16:30 17:30 Chapter 8 – Documentation (plenary session)
Session moderators: Luca Ferrari on behalf of the EBF
17:30 18:15 Chapter 7- Additional Considerations – general topics (plenary session)
Session moderator: Iain Love and Anna Laurén, on behalf of the EBF
18:15 18:30 Short logistic break
18:30 19:00 Chapter 7 – Additional Considerations – Chromatography (breakout session)
Session moderator: Iain Love, on behalf of the EBF
18:30 19:00 Chapter 7 – Additional Considerations – LBA (breakout session)
Session moderators: Anna Laurén, on behalf of the EBF
Slides
Summary slides from the Workshop as presented at the 15th OS
Slides
Public comments submitted to EMA by the EBF during public consultation in 2019
Meeting organisation: Matthew Barfield (F. Hoffmann – La Roche), Kyra Cowan (Merck KGaA), Michaela Golob (Nuvisan), Jo Goodman (AstraZeneca), Robert Nelson (Labcorp), Steve White (GSK) and Philip Timmerman (EBF)
Scroll to Top